BMY vs. ZTS, PFE, ABBV, MRK, GSK, REGN, VRTX, SNY, TAK, and ABT
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Zoetis (ZTS), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), GSK (GSK), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Sanofi (SNY), Takeda Pharmaceutical (TAK), and Abbott Laboratories (ABT). These companies are all part of the "pharmaceutical preparations" industry.
Bristol-Myers Squibb (NYSE:BMY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, community ranking, dividends, valuation and earnings.
Bristol-Myers Squibb has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.
Bristol-Myers Squibb received 180 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.82% of users gave Zoetis an outperform vote while only 66.87% of users gave Bristol-Myers Squibb an outperform vote.
Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.5%. Zoetis pays an annual dividend of $1.73 per share and has a dividend yield of 1.0%. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Zoetis pays out 33.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.
In the previous week, Bristol-Myers Squibb had 16 more articles in the media than Zoetis. MarketBeat recorded 32 mentions for Bristol-Myers Squibb and 16 mentions for Zoetis. Bristol-Myers Squibb's average media sentiment score of 0.78 beat Zoetis' score of 0.55 indicating that Bristol-Myers Squibb is being referred to more favorably in the media.
Zoetis has a net margin of 27.38% compared to Bristol-Myers Squibb's net margin of -13.50%. Zoetis' return on equity of 50.34% beat Bristol-Myers Squibb's return on equity.
Bristol-Myers Squibb presently has a consensus target price of $60.00, suggesting a potential upside of 36.27%. Zoetis has a consensus target price of $211.75, suggesting a potential upside of 21.65%. Given Bristol-Myers Squibb's higher probable upside, equities research analysts plainly believe Bristol-Myers Squibb is more favorable than Zoetis.
76.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Zoetis beats Bristol-Myers Squibb on 12 of the 20 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
